- Dr Robinson explains that since one-third of DLBCL patients fail first-line therapy, the challenges faced by physicians are to improve salvage strategies
- He described novel agents such as B-cell inhibitors, BCL2 inhibitors and disease modifying agents offer new treatment options.
- CAR-T is an emerging therapy showing promising response rates, however, Dr Robinson cautions that longer term data would be needed to assess the efficacy of these agents.
44th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 18-21 March 2018, Lisbon, Portugal
Doctor Stephen Robinson, University Hospitals Bristol NHS Trust, Bristol, UK